Human FGF1ΔHBS Gene Therapy as Treatment for Metabolic Dysfunction-Associated Steatohepatitis in ApoE-KO Mice
Authors:
- Yingjian LiYLYingjian Li
- Xiaodan HuiXHXiaodan Hui
- Chunjie GuCGChunjie Gu
- Qian LinQLQian Lin
- Ahmed Abdelbaset-IsmailAAAhmed Abdelbaset-Ismail
- Zixuan XuZXZixuan Xu
- Suchen YadavSuchen Yadav
- Hongbiao HuangHHHongbiao Huang
- Jason XuJXJason Xu
- Sara E. WatsonSWSara E. Watson
- Kupper A. WintergerstKWKupper A. Wintergerst
- Lu CaiLu Cai
Open Access
Abstract
The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is rising worldwide. hFGF1ΔHBS, a variant of human fibroblast growth factor 1 with three substitutions in its heparin-binding sites, was previously shown by our group to ameliorate fatty liver. However, hFGF1ΔHBS also significantly modulates systemic metabolism, making it unclear whether its hepatic benefits arise from direct liver-specific actions. Additionally, its poor pharmacokinetic profile underscores the need for alternative delivery strategies. Here, we employed adeno-associated virus serotype 8 under the thyroxine-binding globulin promoter (AAV8-TBG) to achieve sustained, hepatocyte-specific expression of hFGF1ΔHBS. In high-fat-, high-cholesterol-diet-fed apolipoprotein E knockout mice, liver-directed hFGF1ΔHBS expression markedly reduced hepatic steatosis, inflammation, and fibrosis, independent of changes in body weight, blood glucose, insulin sensitivity, body composition, or circulating triglyceride and cholesterol levels. Mechanistically, hFGF1ΔHBS gene transfer normalized fatty acid synthesis and suppressed fatty acid uptake by downregulation of stearoyl-CoA desaturase-1 and cluster of differentiation 36. Importantly, these therapeutic effects were achieved without inducing hepatic hyperproliferation, as evidenced by unchanged expression of proliferating cell nuclear antigen and antigen Kiel 67. Collectively, our findings demonstrate that hFGF1ΔHBS exerts direct hepatoprotective effects and that AAV8-TBG-mediated liver-directed hFGF1ΔHBS delivery represents a safe and effective strategy for treating MASH.Keywords
Funding Information
- National Institutes of Health (R01HL125877)
- National Institutes of Health (R01HL160927)
- National Institutes of Health (R01HL174922)
- National Institutes of Health (R01DK131442)
- National Institutes of Health (R01DK115406)
- National Institutes of Health (P30ES030328)
- Kentucky Pediatric Cancer Research Trust Fund (FY 24/25)
- Jewish Heritage Fund for Excellence Research Enhancement Grant Program at the University of Louisville School of Medicine
This publication has 48 references indexed in Scilit:
- The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysisiScience, 2025
- Hepatocyte‐Derived FGF1 Alleviates Isoniazid and Rifampicin‐Induced Liver Injury by Regulating HNF4α‐Mediated Bile Acids SynthesisAdvanced Science, 2024
- FGF1ΔHBS delays the progression of diabetic nephropathy in late-stage type 2 diabetes mouse model by alleviating renal inflammation, fibrosis, and apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in MiceHepatology, 2021
- Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseasesEBioMedicine, 2019
- Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanismKidney International, 2018
- Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer StabilityCell Reports, 2017
- Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction techniqueJournal of Controlled Release, 2016
- Mechanisms of hepatic fibrogenesisBest Practice & Research Clinical Gastroenterology, 2011
- Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits HypothesisHepatology, 2010